FS Reports最新文献

{"title":"Optimal surgical approaches to minimally invasive myomectomy for the fertility patient","authors":"Kathryn Coyne M.D., Zaraq Khan M.B.B.S., Rebecca Flyckt M.D.","doi":"10.1016/j.xfre.2026.08.006","DOIUrl":"10.1016/j.xfre.2026.08.006","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 5","pages":"Pages 346-350"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149162744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole systems traditional Chinese medicine utilization among women undergoing frozen embryo transfers at an academic fertility center","authors":"Samuel N. Rodgers-Melnick Ph.D., M.P.H., Lee Hullender Rubin D.A.O.M., M.S., Sung Tae Kim Ph.D., Lucas D. Jones Ph.D., Rebecca Flyckt M.D., Christine Kaiser D.A.C.M.","doi":"10.1016/j.xfre.2026.06.008","DOIUrl":"10.1016/j.xfre.2026.06.008","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate sociodemographic and clinical variables associated with Whole Systems Traditional Chinese Medicine (WS-TCM) utilization alongside frozen embryo transfers (FETs) after in vitro fertilization.</div></div><div>To investigate sociodemographic and clinical variables associated with Whole Systems Traditional Chinese Medicine (WS-TCM) utilization alongside frozen embryo transfers (FETs) after in vitro fertilization.</div><div><h3>Design</h3><div>We conducted a retrospective review of all autologous FETs performed within an academic medical center’s fertility clinic between January 2019 and March 2024. One FET cycle per patient was randomly selected for analysis. After conducting bivariate analyses, a logistic regression model was employed to examine independent associations with WS-TCM utilization.</div></div><div>We conducted a retrospective review of all autologous FETs performed within an academic medical center’s fertility clinic between January 2019 and March 2024. One FET cycle per patient was randomly selected for analysis. After conducting bivariate analyses, a logistic regression model was employed to examine independent associations with WS-TCM utilization.</div><div><h3>Subjects</h3><div>Women aged 21–42 who underwent an FET after in vitro fertilization. FETs involving donor egg embryos, gestational carriers, and those with missing live birth outcome data were excluded.</div></div><div>Women aged 21–42 who underwent an FET after in vitro fertilization. FETs involving donor egg embryos, gestational carriers, and those with missing live birth outcome data were excluded.</div><div><h3>Exposure</h3><div>Attending ≥1 WS-TCM appointment between 120 days pre- and 12 days post-FET. Whole Systems Traditional Chinese Medicine treatment modalities included individualized acupuncture, nutritional and lifestyle modifications, and focused dietary supplements.</div></div><div>Attending ≥1 WS-TCM appointment between 120 days pre- and 12 days post-FET. Whole Systems Traditional Chinese Medicine treatment modalities included individualized acupuncture, nutritional and lifestyle modifications, and focused dietary supplements.</div><div><h3>Main Outcome Measures</h3><div>Sociodemographic and clinical variables associated with WS-TCM utilization.</div></div><div>Sociodemographic and clinical variables associated with WS-TCM utilization.</div><div><h3>Results</h3><div>Of 799 women studied, 162 (20.3%) utilized WS-TCM, receiving a median of 5.5 treatments between 120 days pre- and 12 days post-FET. Whole Systems Traditional Chinese Medicine users resided in neighborhoods with higher median income ($83,025 vs. $75,602). Previous medical histories of women incorporating WS-TCM included higher rates of migraine/headache (21.6% vs. 13.3%), musculoskeletal pain (37.0% vs. 27.5%), recurrent pregnancy loss (RPL; 25.9% vs. 12.9%), pain associated with genital organs (21.0% vs. 14.1%), and undergoing more assisted reproductive tech","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 5","pages":"Pages 394-403"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149153661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The hidden risk: inadvertent pregnancies in random start ovarian stimulation protocols and ovarian hyperstimulation syndrome","authors":"Ayse Seyhan M.D., Bulent Urman M.D., Baris Ata M.D.","doi":"10.1016/j.xfre.2026.07.006","DOIUrl":"10.1016/j.xfre.2026.07.006","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the risk of severe ovarian hyperstimulation syndrome (OHSS) when random-start ovarian stimulation (RSOS) is performed during an undetected, spontaneously conceived pregnancy.</div></div><div>To examine the risk of severe ovarian hyperstimulation syndrome (OHSS) when random-start ovarian stimulation (RSOS) is performed during an undetected, spontaneously conceived pregnancy.</div><div><h3>Design</h3><div>A case-report</div></div><div>A case-report</div><div><h3>Subjects</h3><div>A 24-year-old woman with polycystic ovary syndrome, a history of two early pregnancy losses, and 25 months of infertility, who underwent in vitro fertilization (IVF) with RSOS at an external fertility clinic.</div></div><div>A 24-year-old woman with polycystic ovary syndrome, a history of two early pregnancy losses, and 25 months of infertility, who underwent in vitro fertilization (IVF) with RSOS at an external fertility clinic.</div><div><h3>Exposure</h3><div>The RSOS begun while an early intrauterine pregnancy was already present but unrecognized.</div></div><div>The RSOS begun while an early intrauterine pregnancy was already present but unrecognized.</div><div><h3>Main Outcome Measures</h3><div>Onset and severity of OHSS, assessed by clinical symptoms, serum human chorionic gonadotropin levels, and the need for hospitalization or intervention.</div></div><div>Onset and severity of OHSS, assessed by clinical symptoms, serum human chorionic gonadotropin levels, and the need for hospitalization or intervention.</div><div><h3>Results</h3><div>Following oocyte retrieval, the patient suffered severe abdominal pain and significant ascites consistent with OHSS and was found to have a concurrent intrauterine pregnancy. Outpatient management failed to control her symptoms, and she required hospitalization and termination of the pregnancy. She conceived naturally six months later and delivered a healthy infant.</div></div><div>Following oocyte retrieval, the patient suffered severe abdominal pain and significant ascites consistent with OHSS and was found to have a concurrent intrauterine pregnancy. Outpatient management failed to control her symptoms, and she required hospitalization and termination of the pregnancy. She conceived naturally six months later and delivered a healthy infant.</div><div><h3>Conclusion</h3><div>This case underscores the significant risk of undetected pregnancies during RSOS, which can lead to severe OHSS. It emphasizes the critical need for vigilant monitoring of progesterone and human chorionic gonadotropin levels and the implementation of strategies to detect potential pregnancies before trigger of oocyte maturation. Clinicians must weigh carefully the benefits of flexible stimulation protocols against the risks of unintended pregnancies, especially in patients with a reasonable chance of achieving spontaneous conception.</div></div><div>This case underscores the significant risk of undetected pregnancies durin","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 5","pages":"Pages 366-371"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149162747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonhormonal management of endometriosis: Role of dopamine D2 receptor agonists in preserving fertility and ovarian function","authors":"Rahi Tinni Basu,&nbsp;Pradip Kumar Mitra M.D., DNB","doi":"10.1016/j.xfre.2026.07.005","DOIUrl":"10.1016/j.xfre.2026.07.005","url":null,"abstract":"<div><div>Dopamine D2 receptor (DRD2) agonists represent a promising targeted, nonhormonal therapeutic strategy for endometriosis. These agents selectively downregulate vascular endothelial growth factor-A signaling, thereby inhibiting the aberrant angiogenesis that supports the survival and proliferation of endometriotic lesions. This review synthesizes preclinical and early clinical evidence on DRD2 targeting, with a focus on the clinical translation of cabergoline and quinagolide. In a randomized, double-blind, placebo-controlled pilot trial, a 6-month cabergoline regimen significantly reduced chronic pelvic pain scores and improved pain relief without serious adverse events. Additionally, post hoc analysis of lesion regression showed that 61.3% of lesions in the quinagolide group demonstrated regression, while ovulatory function was preserved in 93% of participants, consistent with maintenance of the hypothalamic–pituitary–ovarian axis. Collectively, these data suggest that DRD2 agonists may represent a fertility-compatible, mechanistically targeted therapeutic approach and underscore the need for adequately powered phase 3 clinical trials.</div></div><div>Dopamine D2 receptor (DRD2) agonists represent a promising targeted, nonhormonal therapeutic strategy for endometriosis. These agents selectively downregulate vascular endothelial growth factor-A signaling, thereby inhibiting the aberrant angiogenesis that supports the survival and proliferation of endometriotic lesions. This review synthesizes preclinical and early clinical evidence on DRD2 targeting, with a focus on the clinical translation of cabergoline and quinagolide. In a randomized, double-blind, placebo-controlled pilot trial, a 6-month cabergoline regimen significantly reduced chronic pelvic pain scores and improved pain relief without serious adverse events. Additionally, post hoc analysis of lesion regression showed that 61.3% of lesions in the quinagolide group demonstrated regression, while ovulatory function was preserved in 93% of participants, consistent with maintenance of the hypothalamic–pituitary–ovarian axis. Collectively, these data suggest that DRD2 agonists may represent a fertility-compatible, mechanistically targeted therapeutic approach and underscore the need for adequately powered phase 3 clinical trials.</div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 5","pages":"Pages 357-361"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149162748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating concordance of preimplantation genetic testing-whole-genome sequencing with genetic findings in live-born children","authors":"Shenglai Li M.S.,&nbsp;Benjamin Podgursky M.S.,&nbsp;Maria Katz M.S.,&nbsp;Maxwell Silver B.A.,&nbsp;Thomas Giardina B.S.,&nbsp;Adriana Brown M.S.,&nbsp;Nicholas Schuch B.S.,&nbsp;Qinnan Zhang Ph.D.,&nbsp;Peter Uzelac M.D.,&nbsp;Noor Siddiqui M.S.,&nbsp;Yuntao Xia Ph.D.","doi":"10.1016/j.xfre.2026.08.002","DOIUrl":"10.1016/j.xfre.2026.08.002","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To clinically assess concordance between preimplantation genetic testing-whole-genome sequencing (PGT-WGS) and whole-genome sequencing results from corresponding live-born children, including evaluation of genome-wide variants, targeted gene panels, de novo variants, and genetic risk scores.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;To clinically assess concordance between preimplantation genetic testing-whole-genome sequencing (PGT-WGS) and whole-genome sequencing results from corresponding live-born children, including evaluation of genome-wide variants, targeted gene panels, de novo variants, and genetic risk scores.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Patients underwent a standard in vitro fertilization workflow with PGT-WGS. After pregnancy or live birth, patients were contacted for consent to participate in this study. This small study included 10 biopsy-child pairs. Deoxyribonucleic acid (DNA) samples were collected from children, and whole-genome sequencing was performed accordingly. Genetic findings from PGT-WGS were compared with the child’s whole-genome sequencing results. For de novo variant assessment (3 biopsy-child pairs), parental samples were also requested.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Patients underwent a standard in vitro fertilization workflow with PGT-WGS. After pregnancy or live birth, patients were contacted for consent to participate in this study. This small study included 10 biopsy-child pairs. Deoxyribonucleic acid (DNA) samples were collected from children, and whole-genome sequencing was performed accordingly. Genetic findings from PGT-WGS were compared with the child’s whole-genome sequencing results. For de novo variant assessment (3 biopsy-child pairs), parental samples were also requested.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Subjects&lt;/h3&gt;&lt;div&gt;Clinical trophectoderm biopsy samples, corresponding live-born children, and parental DNA samples.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Clinical trophectoderm biopsy samples, corresponding live-born children, and parental DNA samples.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Exposure&lt;/h3&gt;&lt;div&gt;No applicable.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;No applicable.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;Variant concordance across the whole genome and within designated gene panels; concordance of clinically relevant variants and de novo variants; concordance of functionally significant single-nucleotide polymorphisms (SNPs), including &lt;em&gt;HLA&lt;/em&gt; and &lt;em&gt;APOE&lt;/em&gt;; and resulting genetic risk scores.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Variant concordance across the whole genome and within designated gene panels; concordance of clinically relevant variants and de novo variants; concordance of functionally significant single-nucleotide polymorphisms (SNPs), including &lt;em&gt;HLA&lt;/em&gt; and &lt;em&gt;APOE&lt;/em&gt;; and resulting genetic risk scores.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Analysis of single-nucleotide variants (SNVs) and insertions/deletions (indels) identified an average of 3,562,534 variants genome-wide and 2,656 variants within the 1,200-gene panel per embryo-child pair, yielding a sensitivity of 97.6% and a ","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 5","pages":"Pages 409-416"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149162750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linzagolix for Japanese women with uterine fibroids: a randomized, double-blind, placebo-controlled, phase 3 trial","authors":"Tasuku Harada M.D., Ph.D.,&nbsp;Yutaka Osuga M.D., Ph.D.,&nbsp;Hideomi Takahashi M.Ag.,&nbsp;Asuka Kawai B.S.,&nbsp;Fumiya Shimamura M.Eng.","doi":"10.1016/j.xfre.2026.07.003","DOIUrl":"10.1016/j.xfre.2026.07.003","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To evaluate the efficacy, safety, and pharmacodynamics of linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with heavy menstrual bleeding (HMB) and pain because of uterine fibroids.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;To evaluate the efficacy, safety, and pharmacodynamics of linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with heavy menstrual bleeding (HMB) and pain because of uterine fibroids.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Phase 3, multicenter, placebo-controlled, randomized, double-blind, parallel-group, confirmatory study (NCT05445167).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Phase 3, multicenter, placebo-controlled, randomized, double-blind, parallel-group, confirmatory study (NCT05445167).&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Subjects&lt;/h3&gt;&lt;div&gt;Premenopausal Japanese women with HMB and moderate-to-severe pain because of uterine fibroids.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Premenopausal Japanese women with HMB and moderate-to-severe pain because of uterine fibroids.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Intervention&lt;/h3&gt;&lt;div&gt;Patients were randomized 1:1 to once-daily linzagolix 200 mg (n = 48) or placebo (n = 41) for 12 weeks.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Patients were randomized 1:1 to once-daily linzagolix 200 mg (n = 48) or placebo (n = 41) for 12 weeks.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;The primary endpoints were the proportion of patients with a total pictorial blood loss assessment chart (PBAC) score &lt;10 from week 6–12, and the proportion of patients with a maximum numeric rating scale (NRS) score ≤1 during the 28 days before the end of treatment. Secondary endpoints included time to a total PBAC score &lt;10 or maximum NRS score ≤1, analgesic use, blood hemoglobin, myoma and uterine volumes, patient-reported symptom severity and quality of life, and plasma estradiol levels. Safety endpoints included adverse events (AEs) and time to menstrual recovery.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;The primary endpoints were the proportion of patients with a total pictorial blood loss assessment chart (PBAC) score &lt;10 from week 6–12, and the proportion of patients with a maximum numeric rating scale (NRS) score ≤1 during the 28 days before the end of treatment. Secondary endpoints included time to a total PBAC score &lt;10 or maximum NRS score ≤1, analgesic use, blood hemoglobin, myoma and uterine volumes, patient-reported symptom severity and quality of life, and plasma estradiol levels. Safety endpoints included adverse events (AEs) and time to menstrual recovery.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The superiority of linzagolix vs. placebo was demonstrated for both the proportion of patients with a total PBAC score &lt;10 from week 6–12 (91.5% vs. 2.5%; difference [95% confidence interval], 89.0% [76.0–96.2]), and the proportion of patients with a maximum NRS score ≤1 during the 28 days before the end of treatment (70.8% vs. 9.8%; difference, 61.1% [42.1–75.8]). Reductions in HMB and pain with linzagolix were rapidly achieved, occurred alongside improvements in ot","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 5","pages":"Pages 417-424"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149157644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Why do I need to meet with a mental health professional?”: a class format as a novel approach to delivering gamete recipient education","authors":"Shelby Alsup Ph.D.,&nbsp;Julia Conant Psy.D.,&nbsp;Julia Woodward Ph.D.","doi":"10.1016/j.xfre.2026.07.002","DOIUrl":"10.1016/j.xfre.2026.07.002","url":null,"abstract":"&lt;div&gt;&lt;div&gt;The use of donor gametes has increased substantially in recent decades. In response to the psychosocial and both short- and long-term implications of third-party reproduction, the American Society for Reproductive Medicine (ASRM) recommends psychoeducational counseling for recipient parents. Yet mental health referrals are often experienced as anxiety-provoking or discriminatory, particularly among LGBTQ+ individuals and those pursuing solo parenting, reflecting longstanding heteronormative bias in reproductive medicine. The ASRM has called for fertility care models that move beyond mere acceptance toward affirming, patient-centered care. This review describes over 15 years of experience implementing a psychoeducational, class-based model for gamete recipients in an academic medical center and, more recently, a private multisite fertility clinic. We present preliminary findings, highlight patient-centered benefits, outline practical implementation strategies, and discuss limitations of this approach. Preliminary quality improvement data were drawn from a 1-year survey of patients at a private multisite fertility practice who were eligible to complete either a class-based consultation with an embedded clinical psychologist or a traditional individual consultation. Overall, the majority of patients opted into the class format and found the class moderately to extremely helpful. Primary reasons for opting into the class included reduced financial burden, interest in community-building, and the perceptions of greater inclusivity. To better align required psychoeducational counseling with principles of inclusivity and patient-centered care, alternative models are needed. A class-based mental health consultation offers a practical and scalable approach that delivers essential education while reducing fears of judgment, fostering community, and improving access to care. Ongoing research is examining the impact of this model on patient knowledge, confidence, and the perceived inclusivity of care across diverse family types.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;The use of donor gametes has increased substantially in recent decades. In response to the psychosocial and both short- and long-term implications of third-party reproduction, the American Society for Reproductive Medicine (ASRM) recommends psychoeducational counseling for recipient parents. Yet mental health referrals are often experienced as anxiety-provoking or discriminatory, particularly among LGBTQ+ individuals and those pursuing solo parenting, reflecting longstanding heteronormative bias in reproductive medicine. The ASRM has called for fertility care models that move beyond mere acceptance toward affirming, patient-centered care. This review describes over 15 years of experience implementing a psychoeducational, class-based model for gamete recipients in an academic medical center and, more recently, a private multisite fertility clinic. We present preliminary findings, highlight patient-centered ben","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 5","pages":"Pages 351-356"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149162745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “Live birth outcomes after euploid transfer: autologous vs. donor oocyte embryos in patients aged > 35 years","authors":"Preeti Lamba M.D.","doi":"10.1016/j.xfre.2026.03.009","DOIUrl":"10.1016/j.xfre.2026.03.009","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 4","pages":"Page 336"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148718523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Embryo law has entered the mainstream: why reproductive medicine must engage the debate","authors":"Rebecca W. O’Connor J.D. (Director)","doi":"10.1016/j.xfre.2026.06.006","DOIUrl":"10.1016/j.xfre.2026.06.006","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 4","pages":"Pages 258-259"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148718660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contraceptive use and unfulfilled preferences among women ages 15–49 years in the United States, 2022–2023","authors":"Mia R. Zolna M.P.H.,&nbsp;Doris W. Chiu M.P.H.,&nbsp;Megan L. Kavanaugh Dr.P.H","doi":"10.1016/j.xfre.2026.05.002","DOIUrl":"10.1016/j.xfre.2026.05.002","url":null,"abstract":"<div><h3>Objective</h3><div>To update estimates of, and examine the intersection between, method-specific contraceptive use and unfulfilled contraceptive preferences for US women ages 15–49 years since multiple events (e.g., 2019 Title X Final Rule, COVID-19 pandemic) disrupted reproductive health access in the United States. We situate findings within the changing health policy climate and broader evidence base.</div></div><div><h3>Design</h3><div>This secondary analysis uses the recently available 2022–2023 National Survey of Family Growth, a cross-sectional population-based household survey of US women ages 15–49. We conducted multivariable logistic regression analyses to identify associations between individual's characteristics, method-specific contraceptive use, and unfulfilled contraceptive preferences.</div></div><div><h3>Subjects</h3><div>The full sample of female respondents ages 15–49 (n = 5,586) and subsamples: all contraceptive users including permanent female method users (n = 3,163), contraceptive users and single-method users–both excluding those using only permanent female methods to address data constraints (n = 2,564 and n = 1,861 respectively), and contraceptive nonusers (n = 1,451).</div></div><div><h3>Exposure</h3><div>None.</div></div><div><h3>Main Outcome Measures</h3><div>Current contraceptive use, method-specific use accounting for multiple methods, and unfulfilled contraceptive preferences because of cost.</div></div><div><h3>Results</h3><div>In 2022–2023, 57% of women (42.8 million) reported currently using contraception for any reason. The most common methods were oral contraceptive pill (23%), condom (21%), female permanent methods (20%), withdrawal (19%), and intrauterine device (16%). One-quarter (22%) of users reported multiple methods. Thirteen percent of users preferred a different method, and 31% of nonusers preferred to start a method, if cost were not a worry. Higher levels of unfulfilled contraceptive preferences among users were associated with identifying as a sexual minority (adjusted odds ratio [aOR] = 1.63; confidence interval [CI]: 1.17–2.27) and among nonusers younger than age 40 (aOR = 1.58–2.26; CI: 1.02–4.85) or not married or cohabiting (aOR = 2.49; CI: 1.68–3.69). Among single-method users, 23% using coital-dependent methods, 11% using short-acting methods, and 7% using long-acting methods, reported unfulfilled contraceptive preferences.</div></div><div><h3>Conclusion</h3><div>Most US women used their preferred contraceptive method; however, barriers remain. Although trend analyses were not feasible because of changes in survey design, unfulfilled preferences were lower compared with other population-level studies; the extent to which this represents true shifts or shifts in data quality remains unclear. Healthcare systems grounded in sexual and reproductive equity and that reduce costs are needed to increase access to preferred methods.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 4","pages":"Pages 269-279"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148718534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}